GETREAL, a European Union Innovative Medicines Initiative, will host the forum
“How Can Studies That Inform Relative Effectiveness Best Be Incorporated Into Global Drug Development Plans?” on June 19 at 10:45 a.m. as part of the DIA 2014 50th Annual Meeting at the San Diego Convention Center.

The pharmaceutical companies, academics, regulators, health technology assessment (HTA) agencies and patient groups that comprise GETREAL investigate how to use real-world data in drug development. Information drawn from real-life settings helps HTA agencies determine a drug’s relative effectiveness, or evidence that the drug does more good than harm. Without real-world data to inform assessments of relative effectiveness, drug development can be delayed.

“Determining relative effectiveness is a key step in the drug development process,” said Barbara L. Kunz, DIA global chief executive. “Finding ways to incorporate real-world data will expedite the development of treatments that can benefit patients.”

The session’s panelists are Chris Chinn, vice president and head of health investment evidence, European access to medicines at GlaxoSmithKline in the United Kingdom; and Mark Trusheim, executive in residence and visiting scientist at the Massachusetts Institute of Technology and president of Co-Bio Consulting, LLC.